Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fruquintinib + albumin paclitaxel + gemcitabine
- Development stage
- Phase 2
- Lead developer
- HUTCHMED
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy consisting of fruquintinib (a selective VEGFR inhibitor), albumin-bound paclitaxel (a taxane chemotherapy agent), and gemcitabine (a nucleoside analog). This triple combination is being investigated for the treatment of pancreatic cancer, particularly as first-line therapy. The combination aims to leverage the anti-angiogenic properties of fruquintinib alongside the cytotoxic effects of nab-paclitaxel and gemcitabine to enhance treatment efficacy.
- Other names
- fruquintinib + nab-paclitaxel + gemcitabineNABPLAGEM
02
Targets
RNR (Ribonucleotide reductase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on fruquintinib + albumin paclitaxel + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fruquintinib + albumin paclitaxel + gemcitabine.